ERP-EIF Dachfonds becomes cornerstone investor in NGN BioMed Opportunity

European Investment Fund (EIF) has signed a cornerstone commitment in NGN BioMed Opportunity I GmbH and Co Beteiligungs KG, a joint German-American venture capital fund focusing on investments in development stage Life Science companies. The fund is to be managed by NGN Capital, a team consisting of four partners with offices in Heidelberg (Germany) and New York (USA). The team will carry out investments in both European countries (50%) - mainly Germany and German speaking countries - and the USA (50%).

Matthias Ummenhofer, Deputy Head of Division Venture Capital Operations of European Investment Fund, commented We are pleased that the ERP-EIF Dachfonds has committed to NGN BioMed Opportunity I at a moment when the current environment offers interesting opportunities to invest at low entry valuations into high potential development and late stage life science companies. Return prospects in the life science sector, however, very much depend on the companies' access to intelligent and long-term capital, cooperation with big pharma companies and finally exit channels. NGN, with its strong links and establishment in both Europe and the US is well placed to bridge a gap between markets, providing easier access in each direction to portfolio companies.